피하 약물전달 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Subcutaneous Drug Delivery Devices Market Growth & Trends:

The global subcutaneous drug delivery devices market size is expected to reach USD 51.8 billion by 2030, registering to grow at a CAGR of 7.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing prevalence of chronic conditions combined with regular medicine administration to relive disease symptoms has enhanced the demand for in-home drug administration devices. As per the Centers for Disease Control and Prevention (CDC), in 2018, about 54.4 million adults, amounting to 22.7% suffered from arthritis, fibromyalgia, gout, or lupus in the U.S. The CDC further stated that by 2040, an estimated 78.0 million adults accounting for 26.0% will be diagnosed with arthritis.

In addition, a rising number of biologic medicine approvals for the treatment of life-threatening conditions in patients requiring large dose volumes or extended delivery periods accelerate the demand for subcutaneous drug delivery devices. According to the study published by Informa U.K., in February 2019, the total number of medicines in the clinical trial pipeline increased from 53.0% in 2018 to 55.0% in 2019 for parenteral administrations, with an overall decrease in oral medicine formulations from 33.0% in 2018 to 31.0% in 2019.

Subcutaneous Drug Delivery Devices Market Report Highlights:

• North America accounted for the largest revenue share in 2024 owing to the rising prevalence of chronic diseases in the geriatric population and high disposable income
• By product, injection pen is expected to register the highest CAGR during the forecast period owing to ease in providing multi-dose medicine and affordability
• By distribution channel, the retail pharmacies segment accounted for the largest market share as they include large pharmacy chains and attractive schemes and discounts for the novel medicine delivery devices
• Market players are adopting several strategies such as strategic collaborations and product innovations to cater to the increasing patient demand in the global market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution Channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Distribution Channel outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Subcutaneous Drug Delivery Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Increasing production of biologics
    • 3.2.1.3. Increasing product innovations and approvals
    • 3.2.1.4. Increasing focus on self-administration, prevention of needlestick injuries and dosing errors
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced delivery systems
    • 3.2.2.2. Lack of awareness in developing countries
• 3.3. Subcutaneous Drug Delivery Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Subcutaneous Drug Delivery Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Subcutaneous Drug Delivery Devices Market: Product Movement Analysis
• 4.3. Subcutaneous Drug Delivery Devices Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Prefilled Syringes
  • 4.5.1. Prefilled Syringes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Pen Injectors
  • 4.6.1. Pen Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Auto Injectors
  • 4.7.1. Auto Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Wearable Injectors
  • 4.8.1. Wearable Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Needle-free Injectors
  • 4.9.1. Needle-free Injectors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Subcutaneous Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Subcutaneous Drug Delivery Devices Market: Distribution Channel Movement Analysis
• 5.3. Subcutaneous Drug Delivery Devices Market by Distribution Channel Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Hospital Pharmacies
  • 5.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Retail Pharmacies
  • 5.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Online Pharmacies
  • 5.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Subcutaneous Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional Subcutaneous Drug Delivery Devices Market Movement Analysis
• 6.3. Subcutaneous Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Distribution Channel & End-use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Mexico Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Europe
  • 6.5.6. Europe Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. UK
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. UK Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Germany
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Competitive Scenario
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement scenario
    • 6.5.8.5. Germany Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. France
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Competitive Scenario
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement scenario
    • 6.5.9.5. France Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.10. Italy
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Competitive Scenario
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Reimbursement scenario
    • 6.5.10.5. Italy Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.11. Spain
    • 6.5.11.1. Key Country Dynamics
    • 6.5.11.2. Competitive Scenario
    • 6.5.11.3. Regulatory Framework
    • 6.5.11.4. Reimbursement scenario
    • 6.5.11.5. Spain Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.12. Denmark
    • 6.5.12.1. Key Country Dynamics
    • 6.5.12.2. Competitive Scenario
    • 6.5.12.3. Regulatory Framework
    • 6.5.12.4. Reimbursement scenario
    • 6.5.12.5. Denmark Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.13. Sweden
    • 6.5.13.1. Key Country Dynamics
    • 6.5.13.2. Competitive Scenario
    • 6.5.13.3. Regulatory Framework
    • 6.5.13.4. Reimbursement scenario
    • 6.5.13.5. Sweden Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.14. Norway
    • 6.5.14.1. Key Country Dynamics
    • 6.5.14.2. Competitive Scenario
    • 6.5.14.3. Regulatory Framework
    • 6.5.14.4. Reimbursement scenario
    • 6.5.14.5. Norway Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Japan Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. China Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. India Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. South Korea Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Australia Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Thailand Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Brazil Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Argentina Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. South Africa Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Saudi Arabia Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement scenario
    • 6.8.4.5. UAE Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement scenario
    • 6.8.5.5. Kuwait Subcutaneous Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Gerresheimer AG
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Medtronic Plc
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Ypsomed AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Elcam Medical Group
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Novo Nordisk
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Insulet Corporation
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Becton, Dickinson and Company
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. West Pharmaceutical Services, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. PharmaJet
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Unilife Corporation
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Inolife Sciences
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives